特康唑乳膏治疗非白色念珠菌性真菌性阴道炎：一项回顾性分析结果

Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis.

作者信息

Sood G, Nyirjesy P, Weitz M V, Chatwani A

机构信息

Section of Infectious Diseases, Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA.

出版信息

Infect Dis Obstet Gynecol. 2000;8(5-6):240-3. doi: 10.1155/S1064744900000351.

DOI:10.1155/S1064744900000351

PMID:11220485

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1784691/

Abstract

OBJECTIVE

Although it is FDA-approved for use in vulvovaginal candidiasis caused by non-Candida albicans species, terconazole cream has not been been studied in patients with these infections. We sought to assess the clinical and mycological efficacy of terconazole cream in women with non-C. albicans vaginitis.

METHODS

The records of patients who had received a 7-day course of terconazole cream for culture-proved non-C. albicans vaginitis were reviewed. Data with regard to patient demographics, clinical and mycologic response to therapy within 1 month of treatment, and outcome with other antifungal therapies were analyzed.

RESULTS

Twenty-eight patients received terconazole cream for non-C. albicans infections. Three patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received terconazole within the 6 months prior to referral. Overall, there were 20 C. glabrata cases, 3 C. parapsilosis, and 2 C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted a resolution of their symptoms. Prior terconazole use was not associated with treatment failure (P = 0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20 %) patients remained uncured.

CONCLUSIONS

Terconazole cream may be an appropriate first-line treatment for non C. albicans vaginitis, even in patients who have previously received the drug.

摘要

目的

虽然特康唑乳膏已获美国食品药品监督管理局（FDA）批准用于治疗由非白色念珠菌引起的外阴阴道念珠菌病，但尚未对患有这些感染的患者进行研究。我们试图评估特康唑乳膏治疗非白色念珠菌性阴道炎女性患者的临床和真菌学疗效。

方法

回顾接受为期7天的特康唑乳膏治疗且经培养证实为非白色念珠菌性阴道炎患者的记录。分析患者人口统计学数据、治疗1个月内对治疗的临床和真菌学反应以及其他抗真菌治疗的结果。

结果

28例患者接受特康唑乳膏治疗非白色念珠菌感染。3例患者未返回进行随访。中位年龄为45岁。7例（28%）患者未生育。症状的中位持续时间为3年。9例（36%）患者在转诊前6个月内接受过特康唑治疗。总体而言，有20例光滑念珠菌病例、3例近平滑念珠菌和2例葡萄牙念珠菌病例。14例（56%）患者实现真菌学治愈；11例（44%）患者症状缓解。既往使用特康唑与治疗失败无关（P = 0.09）。10例治疗失败的患者随后接受硼酸栓剂治疗；4例（40%）治愈。3例患者中有2例（67%）最终使用氟胞嘧啶乳膏治愈。5例（20%）患者仍未治愈。